READ-ONLY DIGITIZATION RESULT
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
Ann Oncol · 2025-Nov · PMID 40680993
Panel KM_panel提取完成待 EXE 对齐验证
overall survival
Figure 1.. Intention-to-treat analysis of overall survival (key secondary efficacy endpoint). ARPI, androgen receptor pathway inhibitor; CI, confidence interval; no., number; PSMA, prostate-specific membrane antigen.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:49:49+00:00 |